Contribute Try STAT+ Today

Angry over the high price of a prostate cancer drug, Baltimore officials have filed a lawsuit accusing a Johnson & Johnson (JNJ) unit of using “sham” patent litigation to delay the availability of lower-cost generics, forcing the city to spend millions of dollars unnecessarily.

The lawsuit alleges that Janssen Biotech and its partner, British Technology Group, undertook a “ruse” when seeking a patent for its Zytiga medicine by failing to disclose certain information to the U.S. Patent and Trademark Office. And the move made it possible for the drug maker to deflect generic rivals longer than it might have otherwise.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Kudos to our scribe for a careful reading beyond just the headlines – “both lawsuits use nearly identical language in many sections.”

Comments are closed.